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Sialyl-Lewi? (NeuAca2+3Gal/?+4[Fucal~3]GlcNAc] has been identified as a ligand for E-selectm. P-selectm and recently also for L-selectin. 
We have synthesized the stalyl-Lewisx tetrasacchartde by total enzymattc synthesis from N-acetyllactosamine usmg a placental a2+3-sialyltrans- 
ferase specific for type-2 chain acceptors, followed by a cloned human al+3-fucosyhransferase (FucTV. the ‘plasma-type’ nzyme). This procedure 
resulted in the tetrasacchartde m a 61% overall yield. 
Sialyl-LeX: al+3-Fucosyltransferase: a2-13~Sialyltransferase; S lectm 
1. INTRODUCTION 
Several groups have identified the sialyl-LeX determi- 
nant (NeuAca2-+3Gal~1+4[Fuca1+3]GlcNAc-R, 
Scheme 1, structure 2) as a functional ligand for E-, P- 
and L-selectin [l-8]. E- and P-selectin play a role in 
inflammation and clotting by mediating adhesion of 
leukocytes to endothelium and platelets [9,10], while 
L-selectin is involved in lymphocyte homing to periph- 
eral lymph nodes [7,8]. To further establish the nature 
of the adhesive properties and to explore the use of 
sialyl-Lex-containing oligosaccharides as anti-inflam- 
matory drugs it is necessary to test a wide series of such 
oligosaccharides. Therefore a simple and economical 
production procedure is essential. Sialyl-LeX oligosac- 
charides can be obtained by total chemical synthesis, 
total enzymatic synthesis or a combination of the two. 
Two groups have reported the total chemical synthesis 
of sialyl-LeX, [11,12] which is a multistep synthesis and 
results in a < 10% yield. The enzymatic approach to the 
synthesis of sialyl-LeX, however, proceeds stereoselec- 
tively in one step per linkage and is applicable to other, 
more complex, sialyl-Lex-containing structures. The 
biosynthetic pathway of the sialyl-LeX determinant is 
summarized in Scheme 1. Sialylation has to occur be- 
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Scheme 1. Synthesis of 3’-sialyl-IV-acetyllactosamine (1) and the sialyl- 
LeX tetrasaccharide (2). 
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fore fucosylation because none of the known sia- 
lyltransferases can accept fucosylated structures [13- 
151. Recently. the total enzymatic synthesis of sialyl-Le” 
was reported [16]. The cr2+3-sialyltransferase that was 
used for the synthesis of sialyl-lv-acetyllactosamine, 
however, has a preference for type-l chain 
(Gal/Il-+3GlcNAc) substrates and acts only slowly on 
type-2 chains (GalP1+4GlcNAc). The goal of our 
study was to use glycosyltransferases with the proper 
acceptor specificity for the efficient synthesis of sialyl- 
LeX. resulting in a simple and economical production 
procedure. The &+3-sialyltransferase of human pla- 
centa [ 171 has been identified as an enzyme specific for 
type-2 acceptors [18]. In this report. we have used the 
latter enzyme for the synthesis of the 3’-sialyl-N-acetyl- 
lactosamine. The product of this reaction was converted 
into the sialyl-Le’ tetrasaccharide in a high overall yield 
using a particularly efficient recombinant human 
cxl-+3-fucosyltransferase. 
2. MATERIALS AND METHODS 
2 1. ,‘Mutrr1ul.s 
Human placenta was obtamed from the Department of Obstetrics 
and Gynecology, Academic Hospital of the VriJe Universitelt. Amster- 
dam. and stored frozen until use. Plasmid pPROTA-al.3/1 ,4-FTC 
contammg the human al+3/4-fucosyltranrferdse (Fuc-TIII) gene 
[19]. and plasmld pcDNAl-Fuc-TV contammg the human %1+3- 
fucosyltransferaae (Fuc-TV) gene [30] were kindly provided by Dr. 
John Lowe (Howard Hughes Medical Institute. The Liniverslty of 
Michigan MedIcal School. Ann Arbor, MI) Gal~l~4GlcNAc~l-O- 
(CH,),COOCH, was the kind gift of Dr. Ole Hmdsgaul (Umcersity 
of Alberta, Edmonton. Alberta) B-Acetyllactosamme uas obtained 
from Sigma. St. LOUIS. MO and unlabeled CMP-NeuAc has clther 
purchased from Sigma or synthesized using a calf brain CMP-siahc 
acid synthetase preparation as described previously [?I]. GDP-Fuc 
was provided by Dr. Jacques ban Boom. Umverslty of Leaden. The 
Netherlands and \vas synthesized as described [22]. CMP-[‘H]NeuAc 
(18900 Cl/mol), CMP-[“C]NeuAc (1 7 Wmol) and GDP-[‘JC]Fuc 
(125 Cl/mol) Lcerc purchased from DuPont-New England Nuclear and 
diluted with the unlabeled nucleotlde sugar to the desired specific 
radloacti\,lty. a,-Acid glycoprotem was prepared from human plasma 
Cohn fraction V supernatant as described [23] and deslalylated by mild 
acid hydrolqsls (0.1 N trlfluoroacetlc acid. 1 h at 80°C). All other 
chemicals here obtained from commercial sources and were of the 
highest purity available. 
Human placenta was used as a source for a3-ST [17]. Placenta 
membrdncs were prepared a5 described [IS]. Slalyltransferase activity 
was determmed usmg as~alo-r,-AGP as an acceptor [18]. 
2 3. GDP-FIX. Gul/3l --t4GkNA@-R crl+3-Jut o ,~~ltrun.\@usc~ 
A protein A fusion of Fuc-TV was generated m frame by replacing 
the Fuc-TIII sequence m the pPROTA vector with the corresponding 
sequence of the closely related fucosyltransferase V gene The &wzHI 
site m Fuc-TIII. uhlch IS at theJunctIon of the protem A fusion [I91 
1s conserved in Fuc-TV. Thus. vector fragments [5300 bp 
BonlHI(partia1) ,%~~I and 600 bp EwRI (blunted)~~.Y/z~I] from 
pPROTA-a( 1.3/1.4)FTc were ligated to the Fuc-TV fragment (1680 
bp EunlHI %wI) from pcDNAl-Fuc-TV. generatmg plasmid 
pPROTA-Fuc-TV. 
Monolayers of COS-7 cells were grown in 100 mm dishes contammg 
10 ml of Dulbecco’s Modified Eagle media plus 10% fetal bovine 
244 
serum (Glbco/BRL) in a 37°C humldltied 5% CO? atmosphere. At 
50% confluency. cells were transfected with pPROTA-Fuc-TV DNA 
(3Opg per dish) using a CaPO, procedure [24]. After a 38 h expression 
period media were harvested dally for up to 14 days, and cells were 
replenished with additional media. The cells remained adherent during 
this time. and fucosyltransferase assays showed that Fuc-TV WiS 
contmuouslq expressed. Media uere filtered (0.45 pm) and stored at 
4°C until use 
Fuc-TV was collected by passing the harvested media through IgG- 
Sepharose 6 fast Bow beads (Pharmacla). which had been prepared 
according to the manufiacturer’s Instructions. After absorption of the 
enzyme. the beads bvere washed, resuspended m a 50.50 slurry of 50 
mM Trls-HCI. pH 7.4 and stored at 3°C Fucosyltransferase assays 
were performed as described [13] usmg Ga1~1+4GlcNAc~l-O- 
(CH2),COOCH? as an acceptor 
To optimize condltmns for sialylatlon on a preparative scale, small 
volumes containing each of the followmg ingredients were first mixed 
and lyophlhzed, 50 nmol CMP-[7H]NeuAc Il.1 Ciimol), 2 pmol so- 
dium cacodylate buffer pH 7.0: aslalo-cL,-AGP (220 nmol theoretical 
acceptor sites) and 80 nmol ATP, To the dry material 15 mg of freshly 
thawed placenta membrane pellet was added with a spatula together 
with 5 ~1 of H,O. Before mcubatlon at 37°C the components were 
thoroughly mixed with a small plastic stlrring rod. The effects of 
detergent concentration on the actlvlty of the enzyme was studied by 
varymg the Trlton X-100 concentration from 0 to 0.5% (wh) and by 
following product formatIon with time. The effect of EDTA on prod- 
uct formatlon was tested at optimal Triton X-100 concentration and 
incubation time. The optimal Incubation conditions were used for 
sialylation on a preparative scale. 
N-Acetyllactosamme (9 6 mg. 25 ,umol) and CMP-NeuAc (3.1 mg. 
5 pmol) were lyophlllzed from small volumes together with 0.2 mmol 
sodium cdcodylate (pH 7.0). 8 pmol ATP. 20 firno] EDTA and 4 mg 
Trlton X-100. a?-ST ( 1 5 g. 39 mLJ) m the form ofplacenta membranes 
was added and mixed with the other ingredients and 0.5 ml distilled 
water as described m the previous paragraph, and the mixture was 
Incubated at 37°C for ? h. After mcubatlon the reaction mixture was 
diluted with dlstllled water to 12 ml and centrifuged for 15 min at 
30.000 x g. The supernatant was collected and the pellet was washed 
with another 10 ml of distilled Rater and centrifuged agam. The 
second supernatant was combmed with the first. and this was lyophil- 
ized to dryness. taken up m a volume of 1 ml m HZ0 and applied to 
a column (1.6 x 200 cm) of Blo-Gel P-6 (200400 mesh) equilibrated 
and eluted at a flom of 8 ml/h with 50 mM ammomum acetate, pH 5.2, 
at 45°C. Fractions (4 ml) \\ere collected and monitored for sialic acid 
by applymg the thlobarblturic acid procedure (251 on acid-hydrolysed 
ahquots. Fractions containmg the product were pooled as indicated 
m Fig. I, lyophihzed and desalted on a column (1 x 40 cm) of Bio-Gel 
P-2 (200&!00 me3h) run in water The fractions containing the sialylol- 
lgosaccharlde were pooled and lyophllized This resulted III the title 
compound as a white powder. yield 2.1 mg (3.1 fimol: 62% calculated 
from CMP-NeuAc). In order to obtam enough material for the next 
step of the reaction the preparation of slalyl-A’-acetyllactosamine was 
repeated twice. 
A mixture of 3’-sialyl-h’-acetyllactosamme (1) (3.44 mg. 6.58fimol), 
GDP-fucose (4.78 mg. 8.11 pmol). MnC124H,0 (11.87 mg. 60 pmol), 
sodium cacodylate (38 0 mg, 0.3 mmol. pH 6.5) and 490 mU a3-FT 
(m?moblhzed onto 0.6 ml packed volume I&G-sepharose) m 6 ml total 
volume aqueous solution was Incubated for 96 hours at 22°C with 
agitation by gentle rocking of the reactlon vessel. The solids were 
removed by filtration and the resulting filtrate (about 5.7 ml) was 
apphed to a column (1.6 x I96 cm) of Blo-Gel P-1 (100400 mesh) 
equilibrated and &ted at a Ilow of 6 5 ml/h with 500 mM ammonium 
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acetate, pH 6.83, at 25°C. Three ml fractions were collected and 
counted for radioactivity. Fractions containing the product were 
pooled and lyophilized. To remove residual ammonium acetate, two 
additional lyophihzations from HZ0 were performed. This resulted m 
a yield of 5.80 mg (6.54pmol. - 99% calculated from slalyl-N-acetyl- 
lactosamine). 
2.1. ‘H NMR sprctroscop~ 
Prior to ‘H NMR spectroscopic analysis. the oligosacchandes were 
repeatedly exchanged in DzO at room temperature with intermediate 
lyophihzation. Finally. each sample was redissolved in 400 ~1 D20 
(99.96 atom% D. Aldrich, Milwaukee, WI). ‘H NMR spectroscopy 
(0.01% internal acetone, 6 = 2.225 ppm) was performed on a Bruker 
MSL 400 spectrometer (Facility at the Department of Physical and 
Theoretical Chemistry. Vrije Umverslteit, Amsterdam) operating at 
400 MHz at a probe temperature of 300 K Assignments of slalyl-Le* 
ohgosaccharide were essentially the same as reported before [26]. 
3. RESULTS 
3.1. Optimal sialylation conditions 
Optimal activity of the placenta a3-ST which is a 
relatively unstable enzyme [17] was obtained at a Triton 
X-100 concentration of 0.2% (w/v). Increase of the de- 
tergent concentration in the assay mixtures to a final 
concentration of 0.3% or higher slightly inhibited the 
enzyme activity and at the same time increased incorpo- 
ration into endogenous acceptors. EDTA which has 
previously been shown to enhance placental sialyltrans- 
ferase activity [27] was added to a concentration of 10 
mM. This addition appeared to stimulate the activity of 
the sialyltransferase 1.4-fold. Under these conditions 
product was formed at an almost constant rate up to 
3 h. Further incubation did not yield more product and 
led eventually to product degradation possibly due to 
endogenous sialidase activity. 
3.2. Preparation of 3’-siulyl-N-acet~~lluctosumine (1) 
The acceptor substrate N-acetyllactosamine was used 
in large excess (5-fold) over CMP-NeuAc. Sufficient 
enzyme was used to give a calculated 1.5-fold excess 
based on a linear enzyme activity over an incubation 
period of 3 h. After incubation the product was isolated 
by gel filtration (Fig. 1, panel A). Of different batches 
the overall yield based on CMP-NeuAc as the limiting 
substrate ranged from 35 to 65% with an average of 
53%. The ‘H NMR spectrum of 3’-sialyl-N-acetyllacto- 
samine obtained by this procedure indicated a high de- 
gree of purity (95%) with minor resonances of unreacted 
N-acetyllactosamine still present (< 5%). 
3.3. Preparation of siulyl-Lex oligosnccharide (2) 
GDP-fucose was used in moderate excess (1.2-fold) 
over the acceptor sialyl-N-acetyllactosamine. However 
the reaction was performed long enough (96 hours) so 
that most of the acceptor was converted to sialyl-LeX 
and a yield of 99% was obtained (calculated from the 
carbohydrate acceptor). The elution profile on Bio-Gel 
P-2 is shown in Fig. 1, panel B. Examination of the 
profile revealed that while 90% of the available fucose 
0.30 0.40 0.50 0.60 0.70 0.80 0.90 
Relative elution volume (V, V/) 
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Fig. 1 Isolation of oligosaccharide products by gel filtration. (A) 
3’-Slalyl-N-acetyllactosamme (compound 1) was synthesized by enzy- 
matic catalysis using a human placenta a2+3-sialyltransferase prepa- 
ration as described in section 2. The product was isolated by Bio-Gel 
P-6 chromatography as described in section 2 Fractions of 4 ml 
volume were collected and monitored for sialic acid. The arrows mdl- 
cate the elution positions of free slalic acid (1) and N-acetyllactosam- 
me (2). Fractions mdlcated by the bar were pooled to give the product 
which was desalted in a subsequent gel filtration step. (B) Sialyl-Le’ 
ohgosacchande (2) was synthesized enzymatlcally using recombinant 
plasma type al+3-fucosyltransferase. The product was isolated by 
chromatography on a column of Bio-Gel P-2 as described in section 
2. Fractions of 3 ml volume were collected and momtored for radioac- 
tivlty. The arrows indicate the elution positions of 3’-sialyl-N-acetyl- 
lactosamine (1) (3). 3-fucosyl-N-acetyllactosamme (4). GDP-fucose 
and free fucose (co-eluting in this chromatographic system (5). Peaks 
marked with an asterisk mdlcate products of contaminating acceptors. 
Fractions indicated by the bar were pooled to give the product which 
was desalted by lyophihzmg from water several times. 
was transferred to acceptors, four distinct fucose trans- 
fer products were obtained. representing 80.7, 1.9, 0.5 
and 7.4%, respectively, of the total fucose present in the 
reaction mixture. The major peak. representing 80.7% 
of the total fucose present, was identified as sialyl-Le” 
by ‘H NMR analysis (see Fig. 2 and Table I). 
4. DISCUSSION 
So far, several distinct sialyltransferase activities have 
been described that are capable of catalyzing the trans- 
fer of sialic acid from CMP-NeuAc to Gal-R acceptors 
to form a NeuAca2+3Gal-R linkage. The a2-+3sia- 
245 
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Fig. 2. 400 MHz ‘H NMR spectrum of the sialyl-LeX tetrasaccharlde 
lyltransferase (EC 2.4.99.4) specific for Galj?l+3Gal- 
NAcal-Ser/Thr has been purified from porcine sub- 
maxillary glands [28] and human placenta [29], and is 
commercially available. This enzyme has been demon- 
strated to be effective in the synthesis of sialylated type 
1 chains (NeuAca2~3Gal/?l-+3GlcNAc-R), but not 
type 2 structures (NeuAca2+3Gal/31-+4GlcNAc-R) 
[13]. Recently a cDNA for this enzyme has been cloned 
and expressed using a construct in COS-1 cells, produc- 
ing an active sialyltransferase [30]. A second enzyme is 
the Galpl+3/4GlcNAc:CMP-NeuAc a2+3-sialyl- 
transferase (EC 2.4.99.-), which has been purified to 
homogeneity from rat liver [31], recently leading to its 
cloning as a cDNA [32]. This sialyltransferase catalyzes 
sialic acid transfer to both type 1 and type 2 acceptors, 
but has a strong preference for type 1 structures [32,33]. 
The utility of this enzyme for synthesis of sialyl-N-acet- 
yllactosamine (1) has been demonstrated [34], although 
the yields were not high (14 to 47% with an average of 
27% when CMP-NeuAc was the limiting substrate). Re- 
cently, a recombinant form of this sialyltransferase [32] 
was used for a combined chemical and enzymatic syn- 
thesis of sialyl-LeX [16]. However, these authors em- 
ployed an elaborate in situ nucleotide-sugar recycling 
scheme, which makes this production procedure for sia- 
lyl-LeX not a simple one. A third sialyltransferase activ- 
ity is the Gavl+4GlcNAc:CMP-NeuAc o12-+3-sia- 
lyltransferase (EC 2.4.99.6) detected in fetal calf liver, 
embryonic chicken brain, human placenta and several 
other tissues [ 171. Most of these tissues also contain high 
levels of Gavl-+4GlcNAc:CMP-NeuAc a2-+6-sia- 
lyltransferase. Placenta, however, appears to have only 
a minimal level (< 3%) of a2+6_sialyltransferase activ- 
ity [35]. Furthermore, the enzyme in placenta appears 
to have a pronounced preference for type-2 structures 
over type-l structures [18]. Therefore placenta was the 
tissue of choice as a source for this sialyltransferase in 
the synthesis of the sialyl-LeX oligosaccharide. Efforts 
to purify this enzyme have so far not succeeded. Being 
membrane bound, this enzyme needs to be extracted 
with Triton X-100 or other detergents in order to be 
active in vitro, but it is at the same time inactivated once 
extracted from its membrane environment [29]. How- 
ever, we demonstrated that a placenta-derived mem- 
brane fraction is a very useful source of a2+3-sia- 
lyltransferase in the synthesis of sialylated Iliacetyllac- 
tosamine. Reaction of N-acetyllactosamine with CMP- 
NeuAc in the presence of placenta membranes for only 
3 h at 37°C produced the sialylated trisaccharide 1 in 
good yield (35-65%). which was conveniently isolated 
by means of gel filtration. 
Several a3-fucosyltransferase activities have been de- 
scribed to date (see [36,37] for review). With the excep- 
tion of the myeloid enzyme all of them can efficiently 
catalyze fucose transfer to sialyl-N-acetyllactosamine 
(1) to form sialyl-LeX (2). Palcic et al. [13] showed that 
246 
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Table I 
400 MHz ‘H NMR chemical shift values and Jconstants of structural 
reporter group protons of the constituent monosaccharides of 3’- 
slalyl-N-acetyllactosamme and slalyl-Lewis* 
Re- 
porter 
group 
Residue NeuAcaZ+ NeuAca2+ 
3Gapl+4GlcNAc 3Galj?l+4[Fucal+3]- 
GlcNAc 
ppm (Hz) 
H-l GlcNAca 5.206 (J,,> 2.5) 
GlcNAc/!? 4.718 (J,,2 8.1) 
Gala 4.556 (J, Z 7.9) 
Gap 4.551 (J, 1 7.9) 
H-3e 
Fuca 
Fucp 
NeuAc 
H-3a NeuAc 
H-5 
H-6 
NAc 
FucaJ 
Fuca 
FL@ 
GlcNAca 
GlcNAcp 
NeuAc 
2.757 (J3e4 4.6, 
J k,*-l’ 1) 
1.831 (J,,,, and 
J %..3e -12.1) 
2.040 
2.039 
2.032 
5.092 (J, 2 3.6) 
4.722 (J,,: 8.1) 
4.531 (J,,? 7.8) 
4.522 (J, z 7.8) 
5.097 (J,,? 4.0) 
5.092 (J, I 3 6) 
2.764 (J,,, 4.6; 
J,,,,-12.5) 
1.798 CJ,,, and 
J ,,,,,-12.5) 
4 828 (J,,, 6.7) 
1.171 (J5,6 6.7) 
1.166 (JSh 6.7) 
2.032 
2 032 
2.028 
a fucosyltransferase preparation isolated from human 
milk was able to catalyze the synthesis of analogs of 2. 
Fucosylation reactions using this enzyme preparation 
typically proceeded to near-completion (> 95%) within 
72 h at 37°C using 2.2 mU of enzyme and 3.4 equiva- 
lents of GDP-fucose. Another group used a recombi- 
nant form of the Lewis ~1+3/4-fucosyltransferase to 
transfer fucose to analogs of 1 [38]. It was shown that 
the relative rate for fucosylation of 1 was 9.7% com- 
pared to the better substrate, the type 1 acceptor 
Galpl+3GlcNAc [38]. Recently the cDNA thought to 
code for the plasma type al+3-fucosyltransferase was 
cloned [20]. This enzyme was shown to be restricted in 
its action to type 2 sialylated or neutral acceptor mole- 
cules. With the recombinant Lewis a1+3/4-fuco- 
syltransferase (data not shown) we observed severe 
product inhibition at only about 100 ,uM GDP. In our 
work, with the recombinant plasma al+3-fucosyltrans- 
ferase described in this paper, there was little evidence 
of product (GDP) inhibition, and fucosylation reactions 
routinely proceeded to near completion in the presence 
of >mM concentrations of GDP. Thus the plasma type 
fucosyltransferase is far superior for the practical syn- 
thesis of fucosylated N-acetyllactosamine (LeX) bearing 
structures. This advantage has recently also been ex- 
ploited by others in the synthesis of sialyl-LeX contain- 
ing structures [ 161. 
Finally, the use of enzymes as tools for the synthesis 
of oligosaccharides has the great advantage of flexibility 
in producing other more complex variants of sialyl-LeX 
determinants. For instance, di- and tri-antennary struc- 
tures, with sialyl-LeX determinants on each branch. as 
well as elongated polylactosaminoglycan chains with a 
sialyl-LeX determinant and/or internal fucose residues 
can be synthesized by relatively simple extension of the 
method described here for the synthesis of the sialyl-LeX 
tetrasaccharide. Synthesis of these more complex types 
of sialyl-LeX bearing structures is currently in progress. 
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